UK markets close in 18 minutes
  • FTSE 100

    7,017.01
    +69.02 (+0.99%)
     
  • FTSE 250

    22,164.08
    -3.06 (-0.01%)
     
  • AIM

    1,231.97
    -3.69 (-0.30%)
     
  • GBP/EUR

    1.1678
    +0.0041 (+0.35%)
     
  • GBP/USD

    1.4100
    -0.0044 (-0.31%)
     
  • BTC-GBP

    39,563.67
    -154.48 (-0.39%)
     
  • CMC Crypto 200

    1,509.56
    -54.28 (-3.47%)
     
  • S&P 500

    4,107.40
    -44.70 (-1.08%)
     
  • DOW

    33,978.81
    -290.35 (-0.85%)
     
  • CRUDE OIL

    66.42
    +1.14 (+1.75%)
     
  • GOLD FUTURES

    1,826.20
    -9.90 (-0.54%)
     
  • NIKKEI 225

    28,147.51
    -461.08 (-1.61%)
     
  • HANG SENG

    28,231.04
    +217.23 (+0.78%)
     
  • DAX

    15,169.82
    +50.07 (+0.33%)
     
  • CAC 40

    6,284.33
    +16.94 (+0.27%)
     

Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021

  • Oops!
    Something went wrong.
    Please try again later.
Adaptimmune Therapeutics plc
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 22, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the first quarter ended March 31, 2021, before the US markets open on Thursday, May 6, 2021. Following the announcement, the Company will host a live teleconference and webcast at 9:00 a.m. EDT (2:00 p.m. BST) that same day (details below).

The press release will be available in the investor section of Adaptimmune’s corporate website at www.adaptimmune.com. A live webcast of the conference call and replay can be accessed at https://bit.ly/2Ry9DdR.

To participate in the live conference call, please dial (833) 652-5917 (U.S. or Canada) or
+1 (430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (9271335).

About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2021 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts:

Media Relations:

Sébastien Desprez — VP, Communications and Investor Relations
T: +44 1235 430 583
M: +44 7718 453 176
Sebastien.Desprez@adaptimmune.com

Investor Relations:

Juli P. Miller, Ph.D. — Senior Director, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920
Juli.Miller@adaptimmune.com